Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • tonup69
    Associate Professor
    • Apr 2011
    • 20

    Strange Extremely High FPKMs at Random

    I have been running the TOPHAT pipeline for analysis and have had a problem with some EXTREMELY high FPKM values for a few of the samples. Has anyone seen this before? What do these extremely high FPKM values mean? They appear to be artifactual and only appear on one biological replicate typically (although not always the same sample).

  • kopi-o
    Senior Member
    • Feb 2008
    • 319

    #2
    If you have used Cufflinks, you will often find such FPKM values for very short transcripts, like miRNAs. Check if that is the case.

    Comment

    • tonup69
      Associate Professor
      • Apr 2011
      • 20

      #3
      Originally posted by kopi-o View Post
      If you have used Cufflinks, you will often find such FPKM values for very short transcripts, like miRNAs. Check if that is the case.
      How would you check that? Do you know how to select for genes with Log10FPKM>6 as a gene set? That would allow me to look at these things.

      LTR

      Comment

      • baptist
        Junior Member
        • Jan 2013
        • 3

        #4
        tonup69:

        I think in the output directory of cuffdiff, there are files with suffix fpkm_tracking. Maybe you can get what you want from these files?

        Comment

        • gwilymh
          Member
          • Dec 2011
          • 72

          #5
          I have had a similar problem. These massively elevated FPKM values seem to only be reported for the transcripts newly discovered by Cufflinks/TopHat (i.e. transcripts that were not previously annotated).

          In one analysis, for example, the known genes had an average FPKM value of 214.5, and a maximum FPKM value of 147,473. The newly discovered transcripts, however, returned a mean FPKM of 139,234.6 and a maximum of 74,769,200. 2.5% of the new transcripts had vales greater than the maximum FPKM detected for the annotated genes. The results for the new transcripts clearly contain artifacts.

          Does anyone know how or why this occurs? How can it be prevented? How can such artifacts be screened out of downstream analyses?

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 11:41 AM
          0 responses
          9 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          21 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          34 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-09-2026, 10:04 AM
          0 responses
          44 views
          0 reactions
          Last Post SEQadmin2  
          Working...